Period:
Draw Mode:
| Volume | 18,725 |
|
|||||
| News | - | ||||||
| Day High | 1.47 | Low High |
|||||
| Day Low | 1.3738 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NanoViricides Inc | NNVC | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.05 | 3.57% | 1.45 | 14:44:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.45 | 1.3738 | 1.47 | 1.40 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 89 | 18,725 | $ 1.43 | $ 26,812 | - | 1.04 - 2.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:45:07 | 1 | $ 1.45 | USD |
NanoViricides Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 16.92M | 11.67M | - | 0 | -8.11M | -0.69 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NanoViricides News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NNVC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.45 | 1.26 | 1.30 | 19,647 | 0.15 | 11.54% |
| 1 Month | 1.58 | 1.58 | 1.26 | 1.36 | 21,011 | -0.13 | -8.23% |
| 3 Months | 1.12 | 2.00 | 1.10 | 1.53 | 95,135 | 0.33 | 29.46% |
| 6 Months | 1.24 | 2.00 | 1.04 | 1.43 | 72,184 | 0.21 | 16.94% |
| 1 Year | 1.54 | 2.00 | 1.04 | 1.44 | 50,535 | -0.09 | -5.84% |
| 3 Years | 4.06 | 8.71 | 1.04 | 5.40 | 561,424 | -2.61 | -64.29% |
| 5 Years | 0.38 | 19.80 | 0.16045 | 6.90 | 708,597 | 1.07 | 281.58% |
NanoViricides Description
| Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy. |